Enhancement of antitumor immunity by CTLA-4 blockade

Science
D R LeachJ P Allison

Abstract

One reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells. It has recently become apparent that CTLA-4, a second counterreceptor for the B7 family of costimulatory molecules, is a negative regulator of T cell activation. Here, in vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors. Furthermore, this rejection resulted in immunity to a secondary exposure to tumor cells. These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells.

References

Sep 1, 1991·The Journal of Experimental Medicine·P S LinsleyJ A Ledbetter
Jul 16, 1987·Nature·J F BrunetP Golstein
Nov 10, 1995·Science·J P Allison, M F Krummel
Jul 1, 1994·Immunology Today·C H JuneC B Thompson
Jun 1, 1994·Current Opinion in Immunology·J P Allison
Sep 1, 1994·Immunity·M K Jenkins
Aug 1, 1995·The Journal of Experimental Medicine·M F Krummel, J P Allison
Jun 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·S BaskarL H Glimcher
Jan 31, 1995·Proceedings of the National Academy of Sciences of the United States of America·J G GribbenG S Gray
Aug 1, 1994·Immunity·T L WalunasJ A Bluestone
Apr 1, 1994·The Journal of Experimental Medicine·H I LevitskyD M Pardoll
Mar 1, 1994·European Journal of Immunology·V FlamandM Moser
Jan 1, 1993·Annual Review of Immunology·P S Linsley, J A Ledbetter
Oct 1, 1995·Current Opinion in Immunology·J P AllisonD R Leach

❮ Previous
Next ❯

Citations

Jun 30, 1998·International Journal of Cancer. Journal International Du Cancer·A C DiederichsenA C Ostenhom
Nov 10, 1998·European Journal of Immunology·C A ChambersJ P Allison
Nov 11, 1999·European Journal of Immunology·G MagistrelliY Delneste
Sep 1, 1996·Cancer Metastasis Reviews·P F Searle, L S Young
Feb 1, 1997·Immunologic Research·K G HeroldJ A Bluestone
Apr 23, 2005·Cancer Immunology, Immunotherapy : CII·Michael S SabelRichard B Bankert
May 13, 2005·Cancer Immunology, Immunotherapy : CII·Marie RobinRose-Ann Padua
Jun 16, 2007·Cancer Immunology, Immunotherapy : CII·Diego O CrociO Graciela Scharovsky
Dec 5, 2008·Cancer Immunology, Immunotherapy : CII·Ilyssa O GordonThomas F Gajewski
Feb 10, 2009·Cancer Immunology, Immunotherapy : CII·Jeffrey Weber
Jan 18, 2011·Cancer Immunology, Immunotherapy : CII·Kevin DurganYvette E Latchman
Aug 19, 2011·Cancer Immunology, Immunotherapy : CII·Christian U BlankTon N Schumacher
Sep 14, 2011·Cancer Immunology, Immunotherapy : CII·Adam J BogradPrasad S Adusumilli
Feb 10, 2012·Cancer Immunology, Immunotherapy : CII·Sandra SalviMaria Pia Pistillo
Feb 15, 2012·Cancer Immunology, Immunotherapy : CII·Nicolò Rigamonti, Matteo Bellone
Jan 25, 2005·Springer Seminars in Immunopathology·Ena WangFrancesco M Marincola
Sep 30, 2009·International Journal of Colorectal Disease·Peng QiChun-fang Gao
Jan 29, 2011·Cancer Metastasis Reviews·Roch HouotRonald Levy
Nov 15, 2006·Journal of Biomedical Science·Chih-Ping MaoT-C Wu
Aug 5, 2004·Current Oncology Reports·Monica C PanelliFrancesco M Marincola
Aug 11, 2005·Current Oncology Reports·Christian H PoehleinBernard A Fox
Apr 2, 2008·Current Oncology Reports·Michael S LeibowitzRobert L Ferris
Jun 1, 2011·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Sytse J Piersma
Mar 22, 2013·American Journal of Clinical Dermatology·Dragoslav ZikichMichal J Besser
Jul 31, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Takeshi HanagiriFumihiro Tanaka
Sep 21, 2013·Protein Expression and Purification·Cameron L BardlivingCarl A Batt
Apr 1, 1997·Immunopharmacology·T M Petro, S Zhang
Sep 6, 2000·Veterinary Immunology and Immunopathology·I S ChoiE W Collisson
Aug 1, 2000·Immunology Today·M J Glennie, P W Johnson
Aug 1, 1996·International Journal of Immunopharmacology·S Zhang, T M Petro
Jul 24, 2002·Experimental Hematology·Robin E MillerMary J Laughlin
May 23, 2001·Cancer Letters·S IshigamiT Aikou

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.